These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 29145599

  • 21. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC, Muktar H, Effken C, Mahajan PB.
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [Abstract] [Full Text] [Related]

  • 22. Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.
    Chapdelaine A, Mansour AM, Troyanov Y, Williamson DR, Doré M.
    Clin Rheumatol; 2017 Jun; 36(6):1341-1348. PubMed ID: 28130685
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L, Cartwright CS, Wade R, Richards SM, Vora A.
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [Abstract] [Full Text] [Related]

  • 25. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA, Dutch Initiative on Crohn and Colitis.
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [Abstract] [Full Text] [Related]

  • 26. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.
    Kopylov U, Battat R, Benmassaoud A, Paradis-Surprenant L, Seidman EG.
    Dig Dis Sci; 2015 Feb; 60(2):478-84. PubMed ID: 25236422
    [Abstract] [Full Text] [Related]

  • 27. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.
    Mardini HE, Arnold GL.
    J Clin Gastroenterol; 2003 Feb; 36(5):390-5. PubMed ID: 12702978
    [Abstract] [Full Text] [Related]

  • 28. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR.
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [Abstract] [Full Text] [Related]

  • 29. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.
    Jharap B, de Boer N, Vos R, Smid K, Zwiers A, Peters G, Mulder C, Wilhelm A, van Bodegraven A.
    Br J Pharmacol; 2011 Jun; 163(4):722-31. PubMed ID: 21323897
    [Abstract] [Full Text] [Related]

  • 30. Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines.
    Bar-Yoseph H, Waterman M, Almog R, Billiet T, Vermeire S, Ungar B, Yanai H, Dotan I, Ben-Horin S, Chowers Y.
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):69-75. PubMed ID: 27404966
    [Abstract] [Full Text] [Related]

  • 31. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK.
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [Abstract] [Full Text] [Related]

  • 32. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
    Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, Schwab M, Reinisch W.
    Inflamm Bowel Dis; 2013 Mar; 19(3):590-8. PubMed ID: 23388543
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
    Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM.
    Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634
    [Abstract] [Full Text] [Related]

  • 34. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 35. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    Curkovic I, Rentsch KM, Frei P, Fried M, Rogler G, Kullak-Ublick GA, Jetter A.
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1521-31. PubMed ID: 23588559
    [Abstract] [Full Text] [Related]

  • 36. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
    Jagt JZ, Pothof CD, Buiter HJC, van Limbergen JE, van Wijk MP, Benninga MA, de Boer NKH, de Meij TGJ.
    Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
    [Abstract] [Full Text] [Related]

  • 37. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Kang B, Kim TJ, Choi J, Baek SY, Ahn S, Choi R, Lee SY, Choe YH.
    Aliment Pharmacol Ther; 2020 Aug; 52(3):459-470. PubMed ID: 32598049
    [Abstract] [Full Text] [Related]

  • 38. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
    Vikingsson S, Andersson D, Almer S, Peterson C, Hindorf U.
    J Crohns Colitis; 2014 Dec; 8(12):1702-9. PubMed ID: 25239576
    [Abstract] [Full Text] [Related]

  • 39. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML.
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [Abstract] [Full Text] [Related]

  • 40. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
    Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, Oellerich M, von Ahsen N.
    Clin Chem; 2007 Jul; 53(7):1306-14. PubMed ID: 17495015
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.